Literature DB >> 24240726

Low CADM2 expression predicts high recurrence risk of hepatocellular carcinoma patients after hepatectomy.

Sen Yang1, Hong-Li Yan, Qi-Fei Tao, Sheng-Xian Yuan, Guan-Nan Tang, Yuan Yang, Li-Li Wang, Yi-Liang Zhang, Shu-Han Sun, Wei-Ping Zhou.   

Abstract

PURPOSE: To investigate the expression and clinical significance of CADM2 in hepatocellular carcinomas (HCC).
METHODS: The level of expression of CADM2 mRNA was assessed in frozen tumor specimens and adjacent noncancerous tissues from 30 HCC patients by real-time PCR. The protein level was determined by immunohistochemistry on a tissue microarray containing tumor and adjacent noncancerous tissues from 234 HCC patients. Clinicopathological characteristics associated analysis was performed through SPSS18 .
RESULTS: CADM2 was strikingly down regulated in HCC. CADM2 expression was associated with differentiation (P = 0.000), serum alpha-fetoprotein (P = 0.003), vascular invasion (P = 0.001), and hepatitis B surface antigen (HBsAg, P = 0.038). Furthermore, patients with low CADM2 expression had significantly poorer recurrence-free survival (RFS) (40.8 and 34.2 % vs. 56.3 and 50.1 % in 3- and 5-year RFS, respectively, P = 0.005). Subgroup analysis revealed that the difference in RFS between groups with low- and high-CADM2 expression still existed among patients belonging to stage 0 or A of BCLC staging system (P = 0.008), patients with tumor ≤5 cm in size (P = 0.013), and alpha-fetoprotein-negative patients (P = 0.003). Moreover, low expression was more frequently observed in the early recurrence group (within 2 years, P = 0.007). Further multivariate Cox regression analysis indicated that CADM2 expression level, tumor size, tumor number, vascular invasion, HBsAg were independent risk factors for HCC recurrence.
CONCLUSION: CADM2 serves as a novel predictor of RFS in HCC patients after curative resection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24240726     DOI: 10.1007/s00432-013-1536-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma.

Authors:  Min-Jie Ju; Shuang-Jian Qiu; Qiang Gao; Jia Fan; Ming-Yan Cai; Yi-Wei Li; Zhao-You Tang
Journal:  Cancer Sci       Date:  2009-05-04       Impact factor: 6.716

3.  An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Authors:  Y Fong; R L Sun; W Jarnagin; L H Blumgart
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

4.  Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value.

Authors:  G L Grazi; G Ercolani; F Pierangeli; M Del Gaudio; M Cescon; A Cavallari; A Mazziotti
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

5.  Cell adhesion and prostate tumor-suppressor activity of TSLL2/IGSF4C, an immunoglobulin superfamily molecule homologous to TSLC1/IGSF4.

Authors:  Y N Williams; M Masuda; M Sakurai-Yageta; T Maruyama; M Shibuya; Y Murakami
Journal:  Oncogene       Date:  2006-03-09       Impact factor: 9.867

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

7.  Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer.

Authors:  Yuka Takahashi; Miwako Iwai; Taketo Kawai; Atsushi Arakawa; Takeshi Ito; Mika Sakurai-Yageta; Akihiko Ito; Akiteru Goto; Mitsue Saito; Fujio Kasumi; Yoshinori Murakami
Journal:  Breast Cancer       Date:  2011-04-28       Impact factor: 4.239

8.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

9.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

10.  Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity.

Authors:  Farhoud Faraji; Yanli Pang; Renard C Walker; Rosan Nieves Borges; Li Yang; Kent W Hunter
Journal:  PLoS Genet       Date:  2012-09-20       Impact factor: 5.917

View more
  9 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  Genome-wide analysis of DNA methylation in UVB- and DMBA/TPA-induced mouse skin cancer models.

Authors:  Anne Yuqing Yang; Jong Hun Lee; Limin Shu; Chengyue Zhang; Zheng-Yuan Su; Yaoping Lu; Mou-Tuan Huang; Christina Ramirez; Douglas Pung; Ying Huang; Michael Verzi; Ronald P Hart; Ah-Ng Tony Kong
Journal:  Life Sci       Date:  2014-08-02       Impact factor: 5.037

3.  Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma.

Authors:  Jie Chao; Xiao-Fei Zhang; Qiu-Zhong Pan; Jing-Jing Zhao; Shan-Shan Jiang; Ying Wang; Jian-Hua Zhang; Jian-Chuan Xia
Journal:  Med Oncol       Date:  2014-07-04       Impact factor: 3.064

4.  Inorganic Arsenic-induced cellular transformation is coupled with genome wide changes in chromatin structure, transcriptome and splicing patterns.

Authors:  Caitlyn Riedmann; Ye Ma; Manana Melikishvili; Steven Grason Godfrey; Zhou Zhang; Kuey Chu Chen; Eric C Rouchka; Yvonne N Fondufe-Mittendorf
Journal:  BMC Genomics       Date:  2015-03-19       Impact factor: 3.969

5.  CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma.

Authors:  Dongliang Li; Yongjian Zhang; He Zhang; Chao Zhan; Xin Li; Tu Ba; Zini Qiu; Fang E; Guixiang Lv; Chendan Zou; Chuxuan Wang; Lining Si; Chaoxia Zou; Qiang Li; Xu Gao
Journal:  J Exp Clin Cancer Res       Date:  2018-03-05

6.  Genetic variation in CADM2 as a link between psychological traits and obesity.

Authors:  Julia Morris; Mark E S Bailey; Damiano Baldassarre; Breda Cullen; Ulf de Faire; Amy Ferguson; Bruna Gigante; Philippe Giral; Anuj Goel; Nicholas Graham; Anders Hamsten; Steve E Humphries; Keira J A Johnston; Donald M Lyall; Laura M Lyall; Bengt Sennblad; Angela Silveira; Andries J Smit; Elena Tremoli; Fabrizio Veglia; Joey Ward; Hugh Watkins; Daniel J Smith; Rona J Strawbridge
Journal:  Sci Rep       Date:  2019-05-14       Impact factor: 4.379

7.  High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases.

Authors:  Lu Dai; Yi-Hua Li; Ying-Ying Liang; Jian Zhao; Gang Chen; Jun Yin; Pieter E Postmus; Alfredo Addeo; Justin D Blasberg; Concetta Elisa Onesti; Zhi-Wei Liao; Xu-Guang Rao; Hui-Dong Long
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 2.895

8.  Cell adhesion molecule 2 (CADM2) promotes brain metastasis by inducing epithelial-mesenchymal transition (EMT) in human non-small cell lung cancer.

Authors:  Lu Dai; Jian Zhao; Jun Yin; Wenfan Fu; Gang Chen
Journal:  Ann Transl Med       Date:  2020-04

9.  Robust analysis of novel mRNA-lncRNA cross talk based on ceRNA hypothesis uncovers carcinogenic mechanism and promotes diagnostic accuracy in esophageal cancer.

Authors:  Li-Ping Chen; Hong Wang; Yi Zhang; Qiu-Xiang Chen; Tie-Su Lin; Zong-Qin Liu; Yang-Yang Zhou
Journal:  Cancer Manag Res       Date:  2018-12-27       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.